These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37250652)

  • 1. Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum.
    Sivera F; Núñez-Monje V; Campos-Fernández C; Balaguer-Trull I; Robustillo-Villarino M; Aguilar-Zamora M; Garijo-Bufort M; López-Gómez JM; Peña-González C; de la Morena I; Bedoya-Sanchís D; Yankova-Komsalova L; Conesa-Mateos A; Martínez-Cristóbal A; Navarro-Blasco FJ; Senabre-Gallego JM; Alegre-Sancho JJ
    Front Med (Lausanne); 2023; 10():1156557. PubMed ID: 37250652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis.
    Alegre-Sancho JJ; Núñez-Monje V; Campos-Fernández C; Balaguer-Trull I; Robustillo-Villarino M; Aguilar-Zamora M; Garijo-Bufort M; Pedraz-Penalva T; Peña-González C; de la Morena I; Bedoya-Sanchís D; Yankova-Komsalova L; Conesa-Mateos A; Martinez-Cristóbal A; Navarro-Blasco FJ; Senabre-Gallego JM; Sivera F
    Front Med (Lausanne); 2023; 10():1294247. PubMed ID: 38053615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using natural language processing to explore characteristics and management of patients with axial spondyloarthritis and psoriatic arthritis treated under real-world conditions in Spain: SpAINET study.
    Benavent D; Muñoz-Fernández S; De la Morena I; Fernández-Nebro A; Marín-Corral J; Castillo Rosa E; Taberna M; Sanabra C; Sastre C;
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231220818. PubMed ID: 38146537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study.
    Christiansen SN; Horskjær Rasmussen S; Ostergaard M; Pons M; Michelsen B; Pavelka K; Codreanu C; Ciurea A; Glintborg B; Santos MJ; Sari I; Rotar Z; Gudbjornsson B; Macfarlane GJ; Relas H; Iannone F; Laas K; Wallman JK; van de Sande M; Provan SA; Castrejon I; Zavada J; Mogosan C; Nissen MJ; Loft AG; Barcelos A; Erez Y; Pirkmajer KP; Grondal G; Jones GT; Hokkanen AM; Chimenti MS; Vorobjov S; Di Giuseppe D; Kvien TK; Otero-Varela L; van der Horst-Bruinsma I; Hetland ML; Ørnbjerg LM
    RMD Open; 2024 Jul; 10(3):. PubMed ID: 39053949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study.
    Ramonda R; Lorenzin M; Sole Chimenti M; D'Angelo S; Marchesoni A; Salvarani C; Lubrano E; Costa L; Dal Bosco Y; Fracassi E; Ortolan A; Ferraioli M; Carriero A; Visalli E; Bixio R; Desiati F; Bergamini A; Pedrollo E; Doria A; Foti R; Carletto A
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221090310. PubMed ID: 35510168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Survival, Effectiveness and Safety of Secukinumab in Axial Spondyloarthritis up to 4 Years: A Real-Life Single Center Experience.
    Diaconu AD; Pomîrleanu C; Russu M; Strugariu G; Ancuța E; Ciortescu I; Bologa C; Morărașu BC; Constantin M; Ceasovschih A; Șorodoc V; Șorodoc L; Ancuța C
    J Pers Med; 2024 Apr; 14(4):. PubMed ID: 38673044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.
    Michelsen B; Lindström U; Codreanu C; Ciurea A; Zavada J; Loft AG; Pombo-Suarez M; Onen F; Kvien TK; Rotar Z; Santos MJ; Iannone F; Hokkanen AM; Gudbjornsson B; Askling J; Ionescu R; Nissen MJ; Pavelka K; Sanchez-Piedra C; Akar S; Sexton J; Tomsic M; Santos H; Sebastiani M; Österlund J; Geirsson AJ; Macfarlane G; van der Horst-Bruinsma I; Georgiadis S; Brahe CH; Ørnbjerg LM; Hetland ML; Østergaard M
    RMD Open; 2020 Sep; 6(3):. PubMed ID: 32950963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry.
    Moreno-Ramos MJ; Sanchez-Piedra C; Martínez-González O; Rodríguez-Lozano C; Pérez-Garcia C; Freire M; Campos C; Cáliz-Caliz R; Calvo J; Blanco-Madrigal JM; Pérez-Gómez A; Moreno-Martínez MJ; Linares L; Sánchez-Alonso F; Sastré C; Castrejón I
    Rheumatol Ther; 2022 Aug; 9(4):1031-1047. PubMed ID: 35467242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland.
    Mørup MF; Taieb V; Willems D; Rose M; Lyris N; Lamotte M; Gerlier L; Thom H
    J Med Econ; 2024; 27(1):682-696. PubMed ID: 38650583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis.
    Ramonda R; Lorenzin M; Chimenti MS; D'Angelo S; Marchesoni A; Selmi C; Lubrano E; Santo L; Luchetti Gentiloni MM; Atzeni F; Cauli A; Manara M; Rossini M; Foti R; Cozzi G; Scagnellato L; Ferraioli M; Carriero A; Luciano N; Ruzzon F; Fatica M; Fracassi E; Doria A; Foti R; Carletto A
    Front Immunol; 2024; 15():1435599. PubMed ID: 39076975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness and rheumatologist satisfaction with secukinumab in the treatment of patients with axial spondyloarthritis.
    Kiltz U; Keininger DL; Holdsworth EA; Booth N; Howell O; Modi N; Tian H; Conaghan PG
    Clin Rheumatol; 2022 Feb; 41(2):471-481. PubMed ID: 34800174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).
    Kroon FP; van der Burg LR; Ramiro S; Landewé RB; Buchbinder R; Falzon L; van der Heijde D
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010952. PubMed ID: 26186173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network.
    Inman RD; Choquette D; Khraishi M; Gladman DD; Hussein S; Neish D; Leclerc P
    J Rheumatol; 2023 May; 50(5):634-640. PubMed ID: 36642434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers.
    Gentileschi S; Vitale A; Rigante D; Lopalco G; Emmi G; Orlando I; Di Scala G; Sota J; Fabiani C; Frediani B; Galeazzi M; Lapadula G; Iannone F; Cantarini L
    Isr Med Assoc J; 2018 Jul; 20(7):438-441. PubMed ID: 30109794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.
    Christiansen SN; Horskjær Rasmussen S; Pons M; Michelsen B; Glintborg B; Gudbjornsson B; Grondal G; Vencovsky J; Loft AG; Rotar Z; Pirkmajer KP; Nissen MJ; Baranová J; Macfarlane GJ; Jones GT; Iannone F; Caporali R; Laas K; Vorobjov S; Giuseppe DD; Olofsson T; Provan SA; Fagerli KM; Castrejon I; Otero-Varela L; van de Sande M; van der Horst-Bruinsma I; Nordström D; Kuusalo L; Bernardes M; Hetland ML; Østergaard M; Midtbøll Ørnbjerg L
    Semin Arthritis Rheum; 2024 Apr; 65():152388. PubMed ID: 38301349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials.
    Dougados M; Kiltz U; Kivitz A; Pavelka K; Rohrer S; McCreddin S; Quebe-Fehling E; Porter B; Talloczy Z
    Rheumatol Int; 2022 Feb; 42(2):205-213. PubMed ID: 34773130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years.
    Aparicio M; Guillén-Astete CA; López-Medina C; Sastre C; Rodríguez Martínez FJ
    Rheumatol Ther; 2022 Feb; 9(1):73-94. PubMed ID: 34837630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence.
    Braun J; Kiltz U; Bühring B; Baraliakos X
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211041854. PubMed ID: 34471428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.
    Glintborg B; Lindström U; Giuseppe DD; Provan SA; Gudbjornsson B; Hetland ML; Michelsen B; Wallman JK; Aaltonen K; Hokkanen AM; Nordström D; Jørgensen TS; Hansen RL; Geirsson AJ; Grøn KL; Krogh NS; Askling J; Kristensen LE; Jacobsson LTH;
    Arthritis Care Res (Hoboken); 2022 May; 74(5):748-758. PubMed ID: 33253491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.